• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

    6.980 +0.460 (+7.06%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Iovance Biotherapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    23 24 Next >
    News headline image
    Iovance (IOVA) Q2 2026 Earnings Call Transcript ↗
    Record Amtagvi revenue and gross margins signal strong commercial momentum in cell therapy. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher? ↗
    The healthcare stock is now up more than 130% this year. 
    Via The Motley Fool
    News headline image
    Iovance Biotherapeutics Q2 Earnings Call Highlights ↗
    Iovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded... 
    Via MarketBeat
    Topics Earnings
    Iovance Biotherapeutics (NASDAQ:IOVA) Beats Q2 Estimates on Record Revenue, Shares Jump ↗
    Via Chartmill
    IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) Passes Mark Minervini’s Trend Template and High-Growth Momentum Screen ↗
    Via Chartmill
    Iovance Biotherapeutics (NASDAQ:IOVA) Reports Q1 Revenue Beat and Raised Guidance, Yet Stock Slips Pre-Market ↗
    Via Chartmill
    Top stock movements in today's session. ↗
    Via Chartmill
    News headline image
    Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results ↗
    Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares are surging Thursday after the cancer therapy company shattered second-quarter expectations on both the top and bottom lines. Here's what you should... 
    Via Benzinga
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    News headline image
    Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This Stock Is Up 74% This Year: Is It Too Late to Buy? ↗
    The biotech is clearly innovative, but sometimes that's not enough. 
    Via The Motley Fool
    News headline image
    Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
    Heartflow scales AI diagnostics while Iovance drives personalized cancer therapies, each faces unique financial and operational risks in 2026. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
    Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate industry headwinds. 
    Via The Motley Fool
    News headline image
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
    From Biotech Insider
    Via GlobeNewswire
    News headline image
    Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For? ↗
    Tread carefully, but certain factors make this speculative biotech play stand out. 
    Via The Motley Fool
    BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances Delivery-Focused Oncology Platform Amid Growing Interest in Drug-Delivery Technologies
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    How Advanced Drug Delivery Could Improve Existing Cancer Treatments
    Via Investor Brand Network
    News headline image
    How Advanced Drug Delivery Could Improve Existing Cancer Treatments
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Iovance Biotherapeutics to Present at Upcoming Conference
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Iovance (IOVA) Q1 2026 Earnings Transcript ↗
    Iovance (IOVA) Q1 2026 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street ↗
    It could just as well drop by 50% -- or more -- over the next 12 months. 
    Via The Motley Fool
    Topics Death
    News headline image
    Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare? ↗
    This oncology specialist has proven innovative abilities. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    23 24 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.